MD Medical Group opens new clinic in Nizhny Novgorod
MD Medical Group Investments Plc (“MD Medical Group”, “MDMG” or the “Company” – LSE: MDMG), a leading Russian private healthcare provider, announces that it has opened a new clinic in Nizhny Novgorod. Total investment in the project amounted to 60 million roubles.
The Group’s first clinic in Nizhny Novgorod with an area of 600 sq m will offer a wide range of services both in OBGYN (minor gynaecological operations, genetic diagnostics, ultrasound, maternity care, etc.) and in medical services for all family members (urology, andrology, endocrinology, gastroenterology, etc.). Mother&Child Nizhny Novgorod will also focus on infertility treatment providing the whole range of fertility disorder treatment – from initial consultation to assited reproductive technologies with the possibility of vitrification and cryotransfer of embryos; the clinic will have an annual IVF capacity of up to 1,000 cycles. The clinic is also equipped with an operating theatre where endoscopic operations in gynaecology, surgery, and urology will be performed in the day-patient centre.
Mother&Child Nizhny Novgorod has been created to MD Medical Group’s customary high standards of medical care and is fitted with world-class equipment produced by Karl Storz, GE, Olympus, Nikon, MELAG Medizintechnik oHG, and Origio.
Mark Kurtser, CEO of MD Medical Group, said:
“We are pleased to open our first clinic in Nizhny Novgorod – a major industrial centre in Russia with over 1 mln residents. Just like many of our other clinics across Russia, this new facility, the 36th in our network, will offer our core OBGYN services as well as a number of other services. We will also focus on treating infertility by carrying out IVF cycles including under Mandatory Healthcare Insurance programme.“We see the clinic’s opening as the first stage in the consistent strengthening of our positions in Nizhny Novgorod, where we later plan to launch construction of a major multi-disciplinary hospital for which we have already obtained a land plot. This is a proven approach in our development strategy for new regions. Both the opening of the clinic and the planned hospital construction open significant opporutnities for the dynamic development of the Company in Nizhny Novgorod.”
For further information please contact:
|
Investors |
Media |
|
Dmitry Yakushkin
MD Medical Group Investments Plc
Tel: +7 495 331 4120 d.yakushkin@mcclinics.ru |
EM
Tom Blackwell: +7 919 102 9064 Sergii Pershyn: +1 929 855 8188
|
About MD Medical Group
MD Medical Group is a leading provider in the highly attractive Russian private healthcare service market. The company manages 36 modern healthcare facilities, including 5 hospitals and 31 outpatient clinics in Moscow and the Moscow Region, St. Petersburg, Ufa, Perm, Samara and the Samara Region, Irkutsk, Novosibirsk, Irkutsk, Yaroslavl, Ryazan, Kostroma, Novokuznetsk, Krasnoyarsk, Omsk, Barnaul, Vladimir, Tyumen, Voronezh, and Nizhny Novgorod.
The Company’s shares have been listed on the London Stock Exchange (LSE ticker “MDMG”) in the form of Global Depositary Receipts (GDRs) since 12 October 2012.
Forward-Looking Statements:
This press release contains forward looking statements, which are based on the Company’s current expectations and assumptions and may involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. The forward looking statements contained in this press release are based on past trends or activities and should not be taken that such trends or activities will continue in the future. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a number of variables which could cause actual results or trends to differ materially, including, but not limited to: conditions in the market, market position of the Company, earnings, financial position, cash flows, return on capital and operating margins, anticipated investments and economic conditions; the Company’s ability to obtain capital/additional finance; a reduction in demand by customers; an increase in competition; an unexpected decline in revenue or profitability; legislative, fiscal and regulatory developments, including, but not limited to, changes in environmental and health and safety regulations; exchange rate fluctuations; retention of senior management; the maintenance of labour relations; fluctuations in the cost of input costs; and operating and financial restrictions as a result of financing arrangements.
No statement in this press release is intended to constitute a profit forecast, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for the Company. Each forward looking statement relates only as of the date of the particular statement.